Literature DB >> 25795720

Evidence of long-term disease control with panobinostat maintenance in patients with relapsed multiple myeloma.

Enrique M Ocio1, Julio Dávila2, Juan-Carlos Caballero2, Sara Alonso2, Verónica González de la Calle2, Ramón García-Sanz2, Lucien Gazi3, Socrates Opio3, Mónica Jiménez3, Jesús F San-Miguel4, María-Victoria Mateos2.   

Abstract

Entities:  

Keywords:  maintenance; panobinostat; progression-free survival; relapsed multiple myeloma

Mesh：

Substances：

Year:  2015        PMID： 25795720      PMCID： PMC4486244          DOI： 10.3324/haematol.2015.124164

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  12 in total

1.  Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma.

Authors:  Jeffrey L Wolf; David Siegel; Hartmut Goldschmidt; Katharine Hazell; Priscille M Bourquelot; Bourras R Bengoudifa; Jeffrey Matous; Ravi Vij; Margarida de Magalhaes-Silverman; Rafat Abonour; Kenneth C Anderson; Sagar Lonial
Journal:  Leuk Lymphoma       Date:  2012-03-01

2.  Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells.

Authors:  Laurence Catley; Ellen Weisberg; Tanyel Kiziltepe; Yu-Tzu Tai; Teru Hideshima; Paola Neri; Pierfrancesco Tassone; Peter Atadja; Dharminder Chauhan; Nikhil C Munshi; Kenneth C Anderson
Journal:  Blood       Date:  2006-05-25       Impact factor: 22.113

3.  Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma.

Authors:  Jesús F San-Miguel; Paul G Richardson; Andreas Günther; Orhan Sezer; David Siegel; Joan Bladé; Richard LeBlanc; Heather Sutherland; Monika Sopala; Kaushal K Mishra; Song Mu; Priscille M Bourquelot; María Victoria Mateos; Kenneth C Anderson
Journal:  J Clin Oncol       Date:  2013-09-09       Impact factor: 44.544

4.  PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma.

Authors:  Paul G Richardson; Robert L Schlossman; Melissa Alsina; Donna M Weber; Steven E Coutre; Cristina Gasparetto; Sutapa Mukhopadhyay; Michael S Ondovik; Mahmudul Khan; Carole S Paley; Sagar Lonial
Journal:  Blood       Date:  2013-08-15       Impact factor: 22.113

Review 5.  New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG).

Authors:  E M Ocio; P G Richardson; S V Rajkumar; A Palumbo; M V Mateos; R Orlowski; S Kumar; S Usmani; D Roodman; R Niesvizky; H Einsele; K C Anderson; M A Dimopoulos; H Avet-Loiseau; U-H Mellqvist; I Turesson; G Merlini; R Schots; P McCarthy; L Bergsagel; C S Chim; J J Lahuerta; J Shah; A Reiman; J Mikhael; S Zweegman; S Lonial; R Comenzo; W J Chng; P Moreau; P Sonneveld; H Ludwig; B G M Durie; J F S Miguel
Journal:  Leukemia       Date:  2013-11-20       Impact factor: 11.528

6.  Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study.

Authors:  S K Kumar; J H Lee; J J Lahuerta; G Morgan; P G Richardson; J Crowley; J Haessler; J Feather; A Hoering; P Moreau; X LeLeu; C Hulin; S K Klein; P Sonneveld; D Siegel; J Bladé; H Goldschmidt; S Jagannath; J S Miguel; R Orlowski; A Palumbo; O Sezer; S V Rajkumar; B G M Durie
Journal:  Leukemia       Date:  2011-07-29       Impact factor: 11.528

7.  The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance.

Authors:  Patricia Maiso; Xonia Carvajal-Vergara; Enrique M Ocio; Ricardo López-Pérez; Gema Mateo; Norma Gutiérrez; Peter Atadja; Atanasio Pandiella; Jesús F San Miguel
Journal:  Cancer Res       Date:  2006-06-01       Impact factor: 12.701

8.  In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma.

Authors:  Enrique M Ocio; David Vilanova; Peter Atadja; Patricia Maiso; Edvan Crusoe; Diego Fernández-Lázaro; Mercedes Garayoa; Laura San-Segundo; Teresa Hernández-Iglesias; Enrique de Alava; Wenlin Shao; Yung-Mae Yao; Atanasio Pandiella; Jesús F San-Miguel
Journal:  Haematologica       Date:  2009-11-30       Impact factor: 9.941

9.  Improved survival in multiple myeloma and the impact of novel therapies.

Authors:  Shaji K Kumar; S Vincent Rajkumar; Angela Dispenzieri; Martha Q Lacy; Suzanne R Hayman; Francis K Buadi; Steven R Zeldenrust; David Dingli; Stephen J Russell; John A Lust; Philip R Greipp; Robert A Kyle; Morie A Gertz
Journal:  Blood       Date:  2007-11-01       Impact factor: 22.113

Review 10.  The DAC system and associations with multiple myeloma.

Authors:  Enrique M Ocio; Jesús F San Miguel
Journal:  Invest New Drugs       Date:  2010-12-01       Impact factor: 3.850
View more
  4 in total

1.  Dinutuximab and Panobinostat.

Authors:  Ashley Chasick; Dominic A Solimando; J Aubrey Waddell
Journal:  Hosp Pharm       Date:  2015-10-14

Review 2.  HIV-1 Eradication: Early Trials (and Tribulations).

Authors:  Adam M Spivak; Vicente Planelles
Journal:  Trends Mol Med       Date:  2015-12-12       Impact factor: 11.951

Review 3.  Posttransplant maintenance therapy in multiple myeloma: the changing landscape.

Authors:  S Sengsayadeth; F Malard; B N Savani; L Garderet; M Mohty
Journal:  Blood Cancer J       Date:  2017-03-24       Impact factor: 11.037

4.  Phase II trial of single-agent panobinostat consolidation improves responses after sub-optimal transplant outcomes in multiple myeloma.

Authors:  Sridurga Mithraprabhu; Anna Kalff; Kate H Gartlan; Ioanna Savvidou; Tiffany Khong; Malarmathy Ramachandran; Rachel E Cooke; Kathryn Bowen; Geoffrey R Hill; John Reynolds; Andrew Spencer
Journal:  Br J Haematol       Date:  2020-09-18       Impact factor: 6.998
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.